Astrazeneca-Daiichi DATROWAY OKd in EU for Metastatic HR Positive, HER2 Negative Breast Cancer

 

• First approval in the EU for Daiichi Sankyo and AstraZeneca’s DATROWAY based on TROPION-Breast01 trial showing 37% reduction in the risk of disease progression or death versus chemotherapy
• Second DXd antibody drug conjugate approved in EU based on Daiichi Sankyo’s DXd technology

https://www.biospace.com/press-releases/datroway-approved-in-the-eu-for-patients-with-previously-treated-metastatic-hr-positive-her2-negative-breast-cancer